Enactment of FDA Reform Act Improves Drug Safety - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Enactment of FDA Reform Act Improves Drug Safety
New law provides FDA with the resources it needs to safeguard drug supply chain.

Pharmaceutical Technology
Volume 36, Issue 8, pp. 113-114

Industry and FDA collaborate

Among the most significant but least-known developments contributing to this legislative success is the fact that, at a time when company budgets are tight and economic uncertainty runs high, generic-drug producers voluntarily agreed to pay these fees to avoid another heparin-like tragedy. Improving the safety of drugs throughout the supply chain will come at great expense and will only succeed through the diligence of all stakeholders. FDA must be attentive with its drug approval and inspection procedures, and drug producers must remain committed to manufacturing drug ingredients governed by cGMPs. The pharmaceutical industry becomes more global each day, and it becomes increasingly clear that all manufacturers must work to implement quality programs.

As the law is implemented in stages over the next few years, the hope is that the industry will see results from these major steps taken to safeguard the drug supply. The ongoing dialogue between drug manufacturers and FDA has led to a path forward that can hopefully ease the minds of consumers. However, there is more work to be done. Currently, foreign over-the-counter (OTC) drug manufacturing is not being inspected, nor is their inspection included in the passage of the FDA Reform Act. Hopefully, a risk-based inspection approach will be applied to OTC products as well in the future.

John DiLoreto is executive director of the Bulk Pharmaceuticals Task Force, an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA).


1. B. Nychis, Import of Human Drugs and Human Drug Components, CDER Office of Compliance, Office of Drug Security, Integrity & Recalls, Division of Import Operations & Recalls, Import Operations Branch (IOB), Presentation (June 2011).

2. FDA, Pathway to Global Product Safety and Quality, A Special Report, Revised (July 2011).

3. FDA, Drug Safety: FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed, United States Government Accountability Office, Report to the Committee on Oversight and Government Reform, House of Representatives, GAO-10-961 (September 2010).

4. FDA, Fact Sheet: New User Fees for Generic Drugs Will Enhance Americans' Access to Less Expensive Drugs and Generate Major Cost Savings, GDUFA Performance Goals and Efficiency Improvements, Inspection Metrics (July 9, 2012).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here